Associated Papers
Population-Specific Differences in Pathogenic Variants of Genes Associated with Monogenic Parkinson's Disease.
Flores-Ocampo V et al.
Genes, 2025
The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson's disease.
William MB et al.
Npj Parkinson's Disease, 2024
p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe.
Ostrozovicova M et al.
Research Square, 2024
LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X et al.
Biomolecules, 2023
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Exploring the focal role of LRRK2 kinase in Parkinson's disease.
Kumar S et al.
Environmental Science and Pollution Research International, 2022
Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.
Turski P et al.
Frontiers in Neuroscience, 2022
Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY et al.
Journal of Neurochemistry, 2021
LRRK2 mutations in Parkinson's disease patients from Central Europe: A case control study.
Skorvanek M et al.
Parkinsonism & Related Disorders, 2021
Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism.
Chittoor-Vinod VG et al.
International Journal of Molecular Sciences, 2021
Dysfunction of Synaptic Vesicle Endocytosis in Parkinson's Disease.
Zou L et al.
Frontiers in Integrative Neuroscience, 2021
Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.
Li Y et al.
Journal of Human Genetics, 2020
Genetic Risk Factors for Essential Tremor: A Review.
Siokas V et al.
Tremor and Other Hyperkinetic Movements (new York, N.y.), 2020
Progress in LRRK2-Associated Parkinson's Disease Animal Models.
Seegobin SP et al.
Frontiers in Neuroscience, 2020
Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson's Disease.
Cacabelos R et al.
Planta Medica, 2019
The Genetic Diagnosis of Neurodegenerative Diseases and Therapeutic Perspectives.
García JC et al.
Brain Sciences, 2018
LRRK2(I2020T) functional genetic interactors that modify eye degeneration and dopaminergic cell loss in Drosophila.
Marcogliese PC et al.
Human Molecular Genetics, 2017
Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E et al.
Advances in Neurobiology, 2017
Parkinson's disease and age: The obvious but largely unexplored link.
Abdullah R et al.
Experimental Gerontology, 2015
LRRK2 mutations and neurotoxicant susceptibility.
Lee JW et al.
Experimental Biology and Medicine (maywood, N.j.), 2015
Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents.
Daniel G et al.
Current Topics in Behavioral Neurosciences, 2015
Reproducible Analysis of Post-Translational Modifications in Proteomes--Application to Human Mutations.
Holehouse AS et al.
Plos One, 2015
Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
Linhart R et al.
Molecular Neurodegeneration, 2014
Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).
Mills RD et al.
Human Mutation, 2014
Structural and functional in silico analysis of LRRK2 missense substitutions.
Cardona F et al.
Molecular Biology Reports, 2014
Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy.
Hindle S et al.
Human Molecular Genetics, 2013
Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort.
Wu-Chou YH et al.
Parkinsonism & Related Disorders, 2013
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Chen CY et al.
Cell Death and Differentiation, 2012
The genetics and neuropathology of Parkinson's disease.
Houlden H et al.
Acta Neuropathologica, 2012
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
Ray S et al.
Future Medicinal Chemistry, 2012
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T et al.
Acs Chemical Neuroscience, 2012
Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
Vancraenenbroeck R et al.
Biochimica Et Biophysica Acta, 2012
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA et al.
The Lancet. Neurology, 2011
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ et al.
The Biochemical Journal, 2010
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.
Nuytemans K et al.
Human Mutation, 2010
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
Bmb Reports, 2010
Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.
Clark LN et al.
Parkinsonism & Related Disorders, 2010
Identification of four novel potentially Parkinson's disease associated LRRK2 variations among Iranian patients.
Shojaee S et al.
Neuroscience Letters, 2009
Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
Sen S et al.
The Journal of Biological Chemistry, 2009
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
Alcalay RN et al.
Archives of Neurology, 2009
Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.
Venderova K et al.
Human Molecular Genetics, 2009
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
Kumari U et al.
The Febs Journal, 2009
Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN et al.
Journal of Neuroscience Research, 2009
Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson's disease and mutations in PARK2 or PARK8 genes.
Barsottini OG et al.
Arquivos De Neuro-psiquiatria, 2009